Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	98060
Country	Brazil

Received	2024-06-17 02:28
Peer-Review Started	2024-06-17 02:28
To Make the First Decision
Return for Revision	2024-09-10 01:45
Revised	2024-09-14 18:26
Second Decision	2024-10-12 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-12 07:40
Articles in Press	2024-10-12 07:40
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-10-16 14:57
Typeset the Manuscript	2024-10-27 06:15
Publish the Manuscript Online	2024-11-12 12:23

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
Manuscript Source	Invited Manuscript
All Author List	Natalia Centrone and Pedro Luiz Serrano Uson Junior
ORCID	Author(s) ORCID Number Pedro Luiz Serrano Uson Junior http://orcid.org/0000-0001-6122-1374
Funding Agency and Grant Number
Corresponding Author	Pedro Luiz Serrano Uson Junior, MD, Center for Personalized Medicine, Hospital Israelita Albert Einstein, 627/701 Avenue, Albert Einstein, Morumbi, Sao Paulo 05651-901, Brazil. pedroluiz_uson@hotmail.com
Key Words	Hepatocellular carcinoma; Liver cancer; Lenvatinib; Immunotherapy; Checkpoint inhibitors
Core Tip	Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cancer-related death cause, accounting to about 8% of overall cancer deaths. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization is being evaluated associated with systemic treatments including immune checkpoint inhibitors and antiangiogenics. The synergism of these strategies can improve outcomes for patients deemed unresectable and ineligible for transplantation. In this article we will discuss a very interesting combination evaluated in uHCC patients and we will discuss new studies and trials coming forward.
Publish Date	2024-11-12 12:23
Citation	<p>Centrone N, Serrano Uson Junior PL. Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma? <i>World J Gastrointest Oncol</i> 2024; 16(12): 4753-4756</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i12/4753.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i12.4753

Full Article (PDF)	WJGO-16-4753-with-cover.pdf
Manuscript File	98060_Auto_Edited_084736.docx
Answering Reviewers	98060-answering-reviewers.pdf
Audio Core Tip	98060-audio.m4a
Conflict-of-Interest Disclosure Form	98060-conflict-of-interest-statement.pdf
Copyright License Agreement	98060-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	98060-non-native-speakers.pdf
Peer-review Report	98060-peer-reviews.pdf
Scientific Misconduct Check	98060-scientific-misconduct-check.png
Scientific Editor Work List	98060-scientific-editor-work-list.pdf
CrossCheck Report	98060-crosscheck-report.pdf
CrossCheck Report	98060-crosscheck-report.png